Posts

Merck’s exceptional revenue growth in 2021 and the first half of 2022 came thanks to three big brands, one of which is not even approved by the FDA yet.

On Friday, Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.